Plain-English translation of NCT07741071 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing nicotinamide riboside, a naturally occurring compound, to see if it can slow down the progression of early Alzheimer's disease. Researchers will compare people who take this medication every day with people who take a placebo (a pill with no active ingredient) over two years. The goal is to understand whether this treatment can help preserve thinking and memory in people with early-stage Alzheimer's.
Early Alzheimer's disease progresses at different rates in different people, and there are limited treatment options that might slow it down. This trial exists to test whether this medication could offer a new way to help people in the early stages of the disease maintain their cognitive abilities longer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will take either the medication or a placebo capsule by mouth every day for 24 months (two years). You will visit the clinic once every 26 weeks (roughly every six months) for check-ups and tests to see how you are doing and to check for any side effects. Over the course of the trial, you will have about 4–5 clinic visits, and a study partner will help you take the medication and provide information about your daily activities.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
Norway